menu
    • menu
    [{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"CYT-303","moa":"GPC3","graph1":"Oncology","graph2":"Preclinical","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INVO Bioscience \/ INVO Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"INVO Bioscience \/ INVO Bioscience"},{"orgOrder":0,"company":"INVO Bioscience","sponsor":"NAYA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Demerger","leadProduct":"NY-303","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INVO Bioscience \/ INVO Bioscience","highestDevelopmentStatusID":"7","companyTruncated":"INVO Bioscience \/ INVO Bioscience"},{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INVO Bioscience \/ Naya Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"INVO Bioscience \/ Naya Biosciences"},{"orgOrder":0,"company":"INVO Bioscience","sponsor":"Naya Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"INVO Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INVO Bioscience \/ Naya Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"INVO Bioscience \/ Naya Biosciences"}]

    Find Clinical Drug Pipeline Developments & Deals by INVO Bioscience

    Menu

    INVO Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            INVO Bioscience

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            INVO Bioscience

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NY-303

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : NAYA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Demerger

                            DEALS_DEV arrow-down

                            Naya Therapeutics Regains Rights to Cancer Immunotherapy for Clinical Progress

                            Details : NAYA Therapeutics to advance clinical development milestones for its portfolio of first and potential best-in-class candidates, including NY-303, a GPC3/NKp46/CD16 trifunctional antibody for HCC.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            May 29, 2025

                            Lead Product(s) : NY-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : NAYA Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Demerger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            INVO Bioscience

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            INVO Bioscience

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Naya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            INVO and NAYA Bioscience Merge, Will Operate As NAYA Biosciences

                            Details : NAYA Biosciences expands its clinical pipeline to additional regenerative medicine, including clinical stage gene therapy program for leber's hereditary optic neuropathy (LHON).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Naya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            INVO Bioscience

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            INVO Bioscience

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Sponsor : Naya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            NAYA Biosciences to Acquire Clinical Stage Gene Therapy Program for LHON

                            Details : Through the acquisition, NAYA Biosciences expands its clinical pipeline to additional regenerative medicine, including clinical stage gene therapy program for leber's hereditary optic neuropathy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Sponsor : Naya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            INVO Bioscience

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            INVO Bioscience

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CYT-303

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Naya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement To Establish Expanded Publicly Trade...

                            Details : The combined company will work on increasing patient access to life-transforming treatments in oncology, fertility, and regenerative medicine. NAYA Oncology has acquired CYT-303, a clinical-stage bispecific antibody asset for the treatment of Hepatocellu...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 23, 2023

                            Lead Product(s) : CYT-303

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Naya Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth